2025/06/01 by Shellvarajah, Mekala, Nguyen, Vuong, Steinmann, Sarah +3
Medicine · #610 Medicine & #Adherence #Aflibercept #Age-related macular degeneration (AMD) #Anti-VEGF #Disease activity #Medication Adherence and Compliance #Ophthalmology and Visual Impairment Studies #Ranibizumab #Retinal Diseases and Treatments #Visual acuity #health
paper · doi:10.5167/uzh-281149
openalex publication_date 2025/06/01 · openalex created_date 2025/12/11 · openalex updated_date 2026/07/28
Introduction: The evolution of treatment patterns in neovascular age-related macular degeneration (nAMD) warrants investigation into the impact of patients' adherence to anti-vascular endothelial growth factor (VEGF) treatment on visual outcomes. This retrospective, non-randomized, non-comparative study aimed to investigate real-world adherence to anti-VEGF treatment. Results: Overall, 133 patient eyes were included: 129 adherent, and four non-adherent. Mean (standard deviation) baseline VA was 57.0 (23.6) and 53.8 (35.3) letters in adherent and non-adherent patient eyes, respectively. Mean change in VA by month 12 was higher in adherent (6.3 letters) than non-adherent patient eyes (- 11 letters). Compared with the previous visit, adherent visits were associated with a mean increase in VA of 0.67 letters and non-adherent visits with a decrease of 2.30 letters. Conclusions: These results emphasize the importance of adherence to appropriate dosing regimens to optimize visual outcomes in patients with nAMD.